On June 1, 2026, Praxis Precision Medicines reported that their Phase 2/3 POWER1 study for the drug vormatrigine did not meet the primary success measure, but showed a 50% response rate and that about 90% of patients transitioned to an extended study. They are pausing enrollment in a related study to reassess the program.